BR112018014666A2 - compostos de 2-oxindol - Google Patents

compostos de 2-oxindol

Info

Publication number
BR112018014666A2
BR112018014666A2 BR112018014666A BR112018014666A BR112018014666A2 BR 112018014666 A2 BR112018014666 A2 BR 112018014666A2 BR 112018014666 A BR112018014666 A BR 112018014666A BR 112018014666 A BR112018014666 A BR 112018014666A BR 112018014666 A2 BR112018014666 A2 BR 112018014666A2
Authority
BR
Brazil
Prior art keywords
oxindole compounds
oxindole
compounds
ccr
diseases
Prior art date
Application number
BR112018014666A
Other languages
English (en)
Other versions
BR112018014666B1 (pt
Inventor
Yu Chao
R Dragoli Dean
Tanaka Hiroko
P Powers Jay
Yang Ju
Reddy Leleti Manmohan
Zhang Penglie
Fan Pingchen
Singh Rajinder
M Lui Rebecca
Malathong Viengkham
Chen Xi
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of BR112018014666A2 publication Critical patent/BR112018014666A2/pt
Publication of BR112018014666B1 publication Critical patent/BR112018014666B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

a presente invenção refere-se aos compostos de oxindol úteis para o tratamento de condições ou doenças mediadas por ccr (9).
BR112018014666-8A 2016-01-20 2017-01-18 Compostos de 2-oxindol, seu uso e composição farmacêutica BR112018014666B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662280969P 2016-01-20 2016-01-20
US62/280,969 2016-01-20
PCT/US2017/013899 WO2017127409A1 (en) 2016-01-20 2017-01-18 2-oxindole compounds

Publications (2)

Publication Number Publication Date
BR112018014666A2 true BR112018014666A2 (pt) 2018-12-26
BR112018014666B1 BR112018014666B1 (pt) 2024-01-02

Family

ID=59314376

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014666-8A BR112018014666B1 (pt) 2016-01-20 2017-01-18 Compostos de 2-oxindol, seu uso e composição farmacêutica

Country Status (18)

Country Link
US (5) US20170204087A1 (pt)
EP (1) EP3405455B1 (pt)
JP (1) JP6898334B6 (pt)
KR (1) KR20180101565A (pt)
CN (1) CN108698991B (pt)
AR (1) AR107398A1 (pt)
AU (1) AU2017209023B2 (pt)
BR (1) BR112018014666B1 (pt)
CA (1) CA3011639A1 (pt)
IL (1) IL260635B (pt)
MA (1) MA43799A (pt)
MX (1) MX2018008895A (pt)
NZ (1) NZ744468A (pt)
RU (1) RU2743747C2 (pt)
SG (1) SG11201806153QA (pt)
TW (1) TWI729059B (pt)
WO (1) WO2017127409A1 (pt)
ZA (1) ZA201804966B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018014666B1 (pt) 2016-01-20 2024-01-02 Chemocentryx, Inc Compostos de 2-oxindol, seu uso e composição farmacêutica
JP2022539830A (ja) 2019-07-10 2022-09-13 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１阻害剤としてのインダン
WO2021079679A1 (ja) * 2019-10-21 2021-04-29 信越化学工業株式会社 感光性樹脂組成物、感光性ドライフィルム及びパターン形成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
DE69718968T2 (de) 1996-01-17 2003-10-09 Taiho Pharmaceutical Co Ltd 3-(bis-substituierte-phenylmethylen)oxindol-derivate
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
FR2807038B1 (fr) * 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
US7250442B2 (en) 2002-03-15 2007-07-31 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
ATE517102T1 (de) * 2002-11-18 2011-08-15 Chemocentryx Inc Arylsulfonamide
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US8466188B2 (en) 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
FR2909668B1 (fr) * 2006-12-12 2009-01-23 Sanofi Aventis Sa Derives de 5-alkyloxy-indolin-2-one,leur preparation et leurs applications en therapeutique
ATE483685T1 (de) * 2007-02-06 2010-10-15 Novartis Ag 1-benzensulfonyl-1h-indol-derivate als hemmer der ccr9-aktivität
EP2942350A1 (en) * 2008-10-17 2015-11-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2011069298A1 (en) * 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
AU2013225938B2 (en) * 2012-02-29 2017-08-10 Chemocentryx, Inc. Pyrazol-1-yl benzene sulfonamides as CCR9 antagonists
US9715915B2 (en) 2014-10-30 2017-07-25 Samsung Electronics Co., Ltd. Magneto-resistive devices including a free layer having different magnetic properties during operations
BR112018014666B1 (pt) 2016-01-20 2024-01-02 Chemocentryx, Inc Compostos de 2-oxindol, seu uso e composição farmacêutica

Also Published As

Publication number Publication date
RU2018129849A3 (pt) 2020-03-11
EP3405455A4 (en) 2019-07-24
KR20180101565A (ko) 2018-09-12
JP2019502726A (ja) 2019-01-31
US10421748B2 (en) 2019-09-24
US10759789B2 (en) 2020-09-01
US20230119895A1 (en) 2023-04-20
AU2017209023A1 (en) 2018-08-09
EP3405455A1 (en) 2018-11-28
MA43799A (fr) 2021-03-31
RU2018129849A (ru) 2020-02-20
TWI729059B (zh) 2021-06-01
AR107398A1 (es) 2018-04-25
US11434230B2 (en) 2022-09-06
BR112018014666B1 (pt) 2024-01-02
CN108698991A (zh) 2018-10-23
US20210101890A1 (en) 2021-04-08
JP6898334B2 (ja) 2021-07-07
EP3405455B1 (en) 2024-02-28
NZ744468A (en) 2022-07-01
CA3011639A1 (en) 2017-07-27
MX2018008895A (es) 2019-02-13
US20190016709A1 (en) 2019-01-17
US20200123136A1 (en) 2020-04-23
AU2017209023B2 (en) 2021-06-17
JP6898334B6 (ja) 2021-07-28
ZA201804966B (en) 2022-12-21
RU2743747C2 (ru) 2021-02-25
IL260635B (en) 2021-04-29
SG11201806153QA (en) 2018-08-30
CN108698991B (zh) 2022-08-23
WO2017127409A1 (en) 2017-07-27
TW201736345A (zh) 2017-10-16
US20170204087A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
PH12018502329A1 (en) Modulators of the integrated stress pathway
EA201790806A1 (ru) Иммунорегулирующие средства
EA201790998A1 (ru) Иммуннорегуляторные агенты
MX2020004534A (es) Moduladores de la vía integrada del estrés.
BR112017002001A2 (pt) compostos e composição farmacêutica
BR112016028255A2 (pt) agentes imunorreguladores
BR112017012272A2 (pt) derivados de 2-anilinopirimidina como moduladores de egfr
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
SG10201806846RA (en) Cyclopropylamines as lsd1 inhibitors
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
BR112017007012A2 (pt) compostos anti-tnf
PH12017500920A1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas
PH12016501613B1 (en) Pyrazines modulators of gpr6
BR112018014666A2 (pt) compostos de 2-oxindol
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
BR112016028698A2 (pt) preparação de piperidina-4-carbotioamida
EA201791264A1 (ru) Соединения для лечения злокачественного новообразования

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 209/34 , C07D 209/00

Ipc: C07D 209/34 (2006.01), C07D 209/00 (2006.01), C07D

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/01/2017, OBSERVADAS AS CONDICOES LEGAIS